Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $133.2 million.

  • Tarsus Pharmaceuticals' Operating Expenses rose 8180.4% to $133.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $453.5 million, marking a year-over-year increase of 6783.2%. This contributed to the annual value of $303.5 million for FY2024, which is 8898.66% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Operating Expenses stood at $133.2 million for Q3 2025, which was up 8180.4% from $124.8 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Operating Expenses registered a high of $133.2 million during Q3 2025, and its lowest value of $14.7 million during Q2 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Operating Expenses had a median value of $32.8 million in 2023 and averaged $51.8 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Operating Expenses surged by 97261.57% in 2021, and later crashed by 1170.0% in 2022.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Operating Expenses stood at $14.8 million in 2021, then soared by 69.49% to $25.1 million in 2022, then skyrocketed by 129.54% to $57.5 million in 2023, then surged by 57.89% to $90.8 million in 2024, then surged by 46.68% to $133.2 million in 2025.
  • Its Operating Expenses stands at $133.2 million for Q3 2025, versus $124.8 million for Q2 2025 and $104.6 million for Q1 2025.